查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298397

重症肌無力治療市場：按藥物類別、年齡組和分銷渠道：2023-2032 年全球機會分析和行業預測

Myasthenia Gravis Treatment Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 263 Pages | 商品交期: 2-3個工作天內

價格

2022年全球重症肌無力治療市場價值為17億美元，預計2023年至2032年復合年增長率為6.5%，到2032年達到31億美元。

重症肌無力 (MG) 是一種自身免疫性疾病，抗體攻擊並損害神經肌肉接頭處的受體，導致肌肉無力和疲勞。抗體還針對乙□膽鹼受體 (AChR)，這是一種存在於神經肌肉接頭突觸後膜中的蛋白質。此外，在某些情況下，抗體可能會靶向與乙□膽鹼受體 (AChR) 相關的其他蛋白質，例如肌肉特異性激□ (MuSK)。結果，神經和肌肉之間的溝通受到干擾，導致肌肉無力和疲勞。

重症肌無力最常見的症狀包括無力，尤其是眼睛、面部、喉嚨和四肢、說話、吞嚥、呼吸困難、上瞼下垂、複視以及隨著活動而加重的疲勞。目前重症肌無力的治療方法包括乙□膽鹼酯□抑製劑、皮質類固醇、免疫抑製劑、靜脈注射免疫球蛋白（IVIg）和單克隆抗體。

Myasthenia Gravis Treatment Market-IMG1

推動重症肌無力治療市場增長的主要因素是重症肌無力患者數量的增加、自身免疫性疾病診斷技術的進步以及重症肌無力治療選擇的增加。全球重症肌無力患病率上升是推動重症肌無力治療市場增長的主要因素之一。例如，根據美國重症肌無力基金會的數據，美國每 10 萬人中約有 14 至 20 人患有重症肌無力，而且這種疾病在女性中比男性更常見。此外，重症肌無力的患病率在全球範圍內不斷增加，預計這將推動對該疾病有效治療的需求。

此外，重症肌無力診斷的增加預計將推動市場增長。重症肌無力是一種罕見且經常被誤診的自身免疫性疾病，會影響神經肌肉接頭並導致肌肉無力和疲勞。這種疾病可能很難診斷，因為症狀很微妙，而且因人而異。然而，診斷技術的進步使得重症肌無力的診斷更加準確和及時，推動了市場的增長。重症肌無力診斷的激增刺激了對有效治療的需求，推動了市場的增長。隨著越來越多的重症肌無力病例得到早期發現和診斷，越來越需要有效的治療方法來控制疾病和預防並發症。這導致了對重症肌無力新的、更有效的治療方法研發的投資增加。

此外，診斷數量的增加提高了患者和醫療保健專業人員對該疾病的認識。此外，越來越多的專門用於治療重症肌無力的藥物處於臨床開發階段，預計也將推動市場增長。隨著患有重症肌無力的人數不斷增加，對有效治療的需求也在增加，從而產生了對創新治療的需求。這種需求促使製藥公司和研究機構投資開發針對這種疾病的新療法，而臨床試驗已成為測試其安全性和有效性的重要工具。因此，專注於重症肌無力的臨床試驗的激增預計將通過為患有重症肌無力的患者提供新的和改進的治療方法來推動重症肌無力治療市場的增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資口袋
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進者
      • 對重症肌無力有效治療的需求不斷增長
      • 重症肌無力患病率上升
      • 新藥研發進展
    • 阻礙因素
      • 重症肌無力治療的副作用和高費用
    • 機會
      • 新興市場的增長機會
  • COVID-19 市場影響分析

4 重症肌無力治療市場，按藥物類別

  • 概述
    • 市場規模和預測
  • 單克隆抗體
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 靜脈注射免疫球蛋白
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5 重症肌無力治療市場（按年齡組）

  • 概述
    • 市場規模和預測
  • 55歲及以下
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 55+
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家

6 重症肌無力治療市場（按分銷渠道）

  • 概述
    • 市場規模及預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7 重症肌無力治療市場，按地區

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別
    • 市場規模/預測：按年齡段
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按功效等級劃分
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模/預測：按功效等級劃分
    • 市場規模/預測：按年齡段
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按功效等級劃分
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按功效等級劃分
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模/預測：按治療類別
    • 市場規模/預測：按年齡段
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模/預測：按治療類別
    • 市場規模/預測：按年齡段
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 拉丁美洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按功效等級劃分
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分
      • 中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按治療類別
      • 市場規模/預測：按年齡段
      • 市場規模和預測：按分銷渠道劃分

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第九章公司簡介

  • Zydus Lifesciences Limited
  • Novartis AG
  • AstraZeneca
  • Bausch Health Companies, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Astellas Pharma Inc.
  • Kedrion, SpA
  • F. Hoffmann-La Roche Ltd.
Product Code: A11194

The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that attack and damage the receptors at the neuromuscular junction, leading to muscle weakness and fatigue. In addition, the antibodies target the acetylcholine receptor (AChR), which is a protein located on the postsynaptic membrane of the neuromuscular junction. Moreover, in some cases, the antibodies may target other proteins related to the acetylcholine receptor (AChR), such as muscle-specific kinase (MuSK). This leads to impaired communication between the nerve and muscle, which results in muscle weakness and fatigue.

The most common symptoms of myasthenia gravis include muscle weakness, particularly in the eyes, face, throat & limbs, difficulty speaking, swallowing, or breathing, drooping eyelids, double vision, and fatigue that worsens with activity. Currently, there are several drugs available for the treatment of myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIg), and monoclonal antibodies.

Myasthenia Gravis Treatment Market - IMG1

The major factor driving the growth of myasthenia gravis treatment market are increase in number of patients suffering from myasthenia gravis, advancements in diagnosis of autoimmune disorders, and rise in availability of treatment options for myasthenia gravis. The rise in prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 14 to 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men. Moreover, the incidence of myasthenia gravis has increased globally, which is expected to drive the demand for effective treatments for the disease.

Furthermore, increase in the diagnosis of myasthenia gravis is expected to fuel the market growth. Myasthenia gravis is a rare and often misdiagnosed autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. The disease can be challenging to diagnose, as symptoms may be subtle or vary greatly from person to person. However, advancements in diagnostic techniques have led to more accurate and timely diagnosis of myasthenia gravis, which drives the market growth. The surge in the diagnosis of myasthenia gravis has increased the demand for effective treatments and fosters market growth. As more cases of myasthenia gravis are identified and diagnosed earlier, there is a greater need for effective treatments to manage the disease and prevent complications. This has led to increased investment in R&D of new and more effective treatments for myasthenia gravis.

Furthermore, the increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals. In addition, increase in number of drugs in clinical stages of development, focused on treatment of myasthenia gravis is anticipated to boost the growth of market. As the number of people affected by myasthenia gravis continues to increase, the demand for effective treatments rises, resulting in need for innovative therapies. This demand drives the pharmaceutical companies and research institutions to invest in the development of new treatments for the disease, with clinical trials serving as a critical tool for testing their safety and efficacy. Thus, upsurge in number of clinical trials focused on myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market by providing new and improved treatments for patients suffering from myasthenia gravis disease.

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg), and others. On the basis of age group, the market is bifurcated into below 50 years and above 50 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global myasthenia gravis treatment market are: F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. The key players have adopted strategies such as acquisition, agreement, strategic alliance, product approval, and expansion to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Intravenous immunoglobulin
  • Others
  • Monoclonal antibodies

By Age group

  • Below 55 years
  • Above 55 years

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Astellas Pharma Inc.
    • AstraZeneca
    • Bausch Health Companies, Inc.
    • CSL Limited
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Kedrion, SpA
    • Novartis AG
    • Octapharma AG
    • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in demand of effective treatments for myasthenia gravis
      • 3.4.1.2. Surge in prevalence of myasthenia gravis
      • 3.4.1.3. Advancements in R&D of novel drugs
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects and high cost associated with treatments for myasthenia gravis
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Monoclonal antibodies
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Intravenous immunoglobulin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Below 55 years
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Above 55 years
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug class
    • 7.2.3. Market size and forecast, by Age group
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug class
      • 7.2.5.1.3. Market size and forecast, by Age group
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug class
      • 7.2.5.2.3. Market size and forecast, by Age group
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug class
      • 7.2.5.3.3. Market size and forecast, by Age group
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug class
    • 7.3.3. Market size and forecast, by Age group
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug class
      • 7.3.5.1.3. Market size and forecast, by Age group
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug class
      • 7.3.5.2.3. Market size and forecast, by Age group
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug class
      • 7.3.5.3.3. Market size and forecast, by Age group
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug class
      • 7.3.5.4.3. Market size and forecast, by Age group
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug class
      • 7.3.5.5.3. Market size and forecast, by Age group
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug class
      • 7.3.5.6.3. Market size and forecast, by Age group
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug class
    • 7.4.3. Market size and forecast, by Age group
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug class
      • 7.4.5.1.3. Market size and forecast, by Age group
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug class
      • 7.4.5.2.3. Market size and forecast, by Age group
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug class
      • 7.4.5.3.3. Market size and forecast, by Age group
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug class
      • 7.4.5.4.3. Market size and forecast, by Age group
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug class
    • 7.5.3. Market size and forecast, by Age group
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug class
      • 7.5.5.1.3. Market size and forecast, by Age group
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug class
      • 7.5.5.2.3. Market size and forecast, by Age group
      • 7.5.5.2.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Zydus Lifesciences Limited
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Novartis AG
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. AstraZeneca
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Bausch Health Companies, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. CSL Limited
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Grifols, S.A.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Octapharma AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Astellas Pharma Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Kedrion, SpA
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 06. MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 38. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 41. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 60. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 73. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 75. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 76. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 77. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 78. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 79. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 80. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 81. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 82. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 83. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 84. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 85. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 86. ASTRAZENECA: KEY STRATERGIES
  • TABLE 87. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
  • TABLE 88. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
  • TABLE 89. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
  • TABLE 90. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
  • TABLE 91. CSL LIMITED: KEY EXECUTIVES
  • TABLE 92. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 93. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 94. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 95. CSL LIMITED: KEY STRATERGIES
  • TABLE 96. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 97. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 98. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 99. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 100. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 101. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 102. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 103. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 104. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 105. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 106. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 107. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 108. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 109. KEDRION, SPA: KEY EXECUTIVES
  • TABLE 110. KEDRION, SPA: COMPANY SNAPSHOT
  • TABLE 111. KEDRION, SPA: PRODUCT SEGMENTS
  • TABLE 112. KEDRION, SPA: PRODUCT PORTFOLIO
  • TABLE 113. KEDRION, SPA: KEY STRATERGIES
  • TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 115. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 116. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 117. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. MYASTHENIA GRAVIS TREATMENT MARKET BY REGION, 2022
  • FIGURE 22. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: MYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 45. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 46. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)